tirzepatide surmount-1 weight loss percent 72 weeks SURMOUNT-1: Drastically Reduces in Obese Patients surmount-1 week 12 weight loss

Expected Results (According to Clinical Trials) Retatrutide has generated significant scientific interest due to its robust efficacy signals in early clinical trials: Weight reduction: Clinical data have shown that patients receiving higher titration doses experienced substantial weight loss, in some cases exceeding 20% of baseline body weight over extended treatment periods

New England Journal of Medicine, 384(11), 989-1002

While GLP-1 drugs may offer neuroprotective effects relevant to glaucoma, the impact of dual-incretin therapies like tirzepatide on glaucoma remains unknown

Back Diem, P, Ducluzeau, PH, Scheen, A (Jan-March 2022) 'The discovery of insulin', Diabetes, Epidemiology and Management , 5, 100049